Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lutwin Weitner

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Antiviral Therapy|October 26, 2011
Resistance data in the ARTEN trialChristian Hoffmann, Carl Knud Schewe, Lutwin Weitner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 3, 2005
Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatmentCarl Knud Schewe, Renato Maserati, Gernot Wassmer, et al.
AIDS (London, England)|December 4, 2004
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatmentOliver Schildgen, Carl Knud Schewe, Martin Vogel, et al.
The Journal of Infection|November 5, 2005
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patientsEsther Voigt, Christian Schulz, Gerd Klausen, et al.
Antiviral Therapy|September 9, 2011
Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life settingThomas Reiberger, Martin Obermeier, Berit A Payer, et al.
AIDS (London, England)|July 20, 2002
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)Hans-Jürgen Stellbrink, Jan van Lunzen, Michael Westby, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Antiviral Therapy|October 26, 2011
Resistance data in the ARTEN trialChristian Hoffmann, Carl Knud Schewe, Lutwin Weitner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 3, 2005
Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatmentCarl Knud Schewe, Renato Maserati, Gernot Wassmer, et al.
AIDS (London, England)|December 4, 2004
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatmentOliver Schildgen, Carl Knud Schewe, Martin Vogel, et al.
The Journal of Infection|November 5, 2005
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patientsEsther Voigt, Christian Schulz, Gerd Klausen, et al.
Antiviral Therapy|September 9, 2011
Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life settingThomas Reiberger, Martin Obermeier, Berit A Payer, et al.
AIDS (London, England)|July 20, 2002
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)Hans-Jürgen Stellbrink, Jan van Lunzen, Michael Westby, et al.
Pageof 1